- Home
- GGAL vs LEGN Comparison
GGAL vs LEGN Comparison
Compare GGAL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | LEGN |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GGAL | LEGN |
|---|---|---|
| Price | $54.72 | $22.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $67.50 | ★ $69.58 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $3,630,934,738.00 | $909,045,000.00 |
| Revenue This Year | $12.64 | $68.83 |
| Revenue Next Year | $18.04 | $51.27 |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $25.89 | $21.19 |
| 52 Week High | $74.00 | $45.30 |
Technical Indicators
Market Signals| Indicator | GGAL | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 33.24 |
| Support Level | $53.26 | $21.19 |
| Resistance Level | $55.28 | $23.24 |
| Average True Range (ATR) | 1.90 | 1.04 |
| MACD | 0.33 | 0.18 |
| Stochastic Oscillator | 89.29 | 20.29 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.